Overview


A neuroinvasive infection occurs when a pathogenic bacterium, virus, fungus, or parasite spreads through the bloodstream and reaches the spinal cord or brain. As the causative organism accumulates in the fluids or linings of the brain and spinal cord, it develops into a more serious and advanced infection. Several euro-invasive diseases, such as West Nile disease, are highly fatal. Mosquito bites infected with West Nile disease transmit the disease to humans. Meningitis and encephalitis are common types of inflammation caused by neuro-invasive infections. Meningitis' increased prevalence throughout the world contributes to the growth of the neuro-invasive infection market. There are many pathogens that can cause meningitis, including viruses, bacteria, and fungi. Furthermore, pathogenic meningitis is highly communicable, which means it spreads easily from person to person. Consequently, the neuro-invasive infection market has grown. There is another condition that causes inflammation of the brain tissue called encephalitis. Viral causes include herpes simplex viruses, varicella-zoster viruses, and possibly Zika viruses. Another factor boosting the growth of the neuro-invasive infection market is the increased spread of these viruses, particularly in Africa. The lack of distribution channels and diagnostic tests for different pathogens that can cause neuro-invasive infections, however, is hindering the market's growth. In addition, commonly used drugs such as hydroxychloroquine have seen a dramatic increase in demand for managing COVID-19. Due to the high demand for these drugs, manufacturers of COVID-19 management drugs are facing a shortage in many developed countries. Consequently, the pharmaceutical and biotechnology industries will experience significant growth in the future due to the demand for vaccines and treatment drugs for COVID-19. The supply chain of raw materials required to manufacture drugs for neuro-invasive infections has been disrupted in many countries because of COVID-19. Furthermore, due to the pandemic, pharmaceutical manufacturers have slowed down their production, which is resulting in a decline in pharmaceutical market growth. It is anticipated that this will have a significant impact on the neuro-invasive infection market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Neuro-invasive Infection Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Neuro-invasive Infection Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc
  • Bavarian Nordic A/S
  • Mylan N.V.
  • GlaxoSmithKline Plc
  • Teva Pharmaceutical Industries Ltd
  • Heritage Pharma
  • Zydus Cadila Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Meningitis
  • Encephalitis
  • Acute Flaccid Paralysis

By Diagnosis

  • Four-fold Virus-Specific Serum Antibody Titer
  • Enzyme Immunoassay (EIA)
  • Antibody-capture Enzyme Immunoassay

By Treatment

  • Antiviral Agents
  • Steroid Injection
  • Immunoglobulin Therapy
  • Plasmapheresis
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Neuro-invasive Infection Market By Type, By Diagnosis, By Treatment and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Neuro-invasive Infection Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Neuro-invasive Infection Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Neuro-invasive Infection Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Neuro-invasive Infection Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Meningitis
        2. Encephalitis
        3. Acute Flaccid Paralysis

  • 8.   Neuro-invasive Infection Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Four-fold Virus-Specific Serum Antibody Titer
        2. Enzyme Immunoassay (EIA)
        3. Antibody-capture Enzyme Immunoassay

  • 9.   Neuro-invasive Infection Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antiviral Agents
        2. Steroid Injection
        3. Immunoglobulin Therapy
        4. Plasmapheresis
        5. Others

  • 10.   North America Neuro-invasive Infection Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Neuro-invasive Infection Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Neuro-invasive Infection Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Neuro-invasive Infection Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bavarian Nordic A/s
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Mylan N.v.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Glaxosmithkline Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Heritage Pharma
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Zydus Cadila Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients